Ratings by Raymond James (Elliot Wilbur)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/9/2023 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2023 | Organon & Co. | OGN | New Coverage | Outperform (N/A) |
21.95 (18.42) |
-16.08% | Details | |
| 3/14/2023 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/6/2023 | Perrigo Co. | PRGO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/9/2022 | Perrigo Co. | PRGO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/25/2022 | PetIQ Inc. | PETQ | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2022 | Perrigo Co. | PRGO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2022 | PolyPid Ltd. | PYPD | Downgrade | Outperform (Strong Buy) |
5.39 (4.81) |
-10.76% | Details | |
| 8/9/2022 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | PolyPid Ltd. | PYPD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/4/2022 | Perrigo Co. | PRGO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2022 | Antares Pharma | ATRS | Downgrade | Market Perform (Outperform) |
3.74 (5.59) |
49.47% | Details | |
| 4/1/2022 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/16/2022 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2022 | PLx Pharma | PLXP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Virtus Investment Partners | VRTS | Downgrade | Market Perform (Outperform) |
240.62 (230.41) |
-4.24% | Details | |
| 12/7/2021 | PLx Pharma | PLXP | Upgrade | Outperform (Market Perform) |
8.70 (0.09) |
-98.97% | Details | |
| 12/7/2021 | PLx Pharma | PLXP | Upgrade | Outperform (Market Perform) |
8.18 (0.09) |
-98.9% | Details | |
| 11/12/2021 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/11/2021 | Perrigo Co. | PRGO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2021 | ADMA Biologics | ADMA | Upgrade | Outperform (Outperform) |
1.42 (6.44) |
353.52% | Details | |
| 10/28/2021 | Teva Pharma | TEVA | Downgrade | Market Perform (Outperform) |
8.93 (13.25) |
48.38% | Details | |
| 10/26/2021 | ADMA Biologics | ADMA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2021 | Perrigo Co. | PRGO | Upgrade | Outperform (Market Perform) |
44.92 (31.27) |
-30.39% | Details | |
| 10/12/2021 | Flexion Therapeutics | FLXN | Downgrade | Market Perform (Strong Buy) |
5.78 (9.12) |
57.79% | Details | |
| 7/14/2021 | Perrigo Co. | PRGO | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/10/2021 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2021 | Flexion Therapeutics | FLXN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/26/2021 | ADMA Biologics | ADMA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2020 | PolyPid Ltd. | PYPD | Upgrade | Strong Buy (Outperform) |
9.20 (4.81) |
-47.72% | Details | |
| 10/7/2020 | Elanco Animal Health | ELAN | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/3/2020 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2020 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2020 | Antares Pharma | ATRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/28/2020 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2020 | Mylan | MYL | Maintain | Outperform (N/A) |
|
Details | ||
| 12/30/2019 | Sol Gel Technologies Ltd. | SLGL | Maintain | Outperform (N/A) |
|
Details | ||
| 12/27/2019 | Flexion Therapeutics | FLXN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/19/2019 | Akorn | AKRX | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/12/2019 | Amneal Pharmaceuticals | AMRX | Downgrade | Market Perform (Outperform) |
1.59 (5448.90) |
342598.11% | Details | |
| 11/26/2019 | Adamis Pharmaceuticals | ADMP | Downgrade | Market Perform (Outperform) |
1.26 (0.78) |
-38.1% | Details | |
| 11/7/2019 | Amneal Pharmaceuticals | AMRX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2019 | ANI Pharmaceuticals | ANIP | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2019 | Teligent | TLGT | Downgrade | Market Perform (Outperform) |
0.94 (0.17) |
-81.91% | Details | |
| 8/14/2019 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/9/2019 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/21/2019 | Amneal Pharmaceuticals | AMRX | Upgrade | Strong Buy (Market Perform) |
8.57 (6.81) |
-20.54% | Details | |
| 5/10/2019 | Adamis Pharmaceuticals | ADMP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2019 | ANI Pharmaceuticals | ANIP | Downgrade | Outperform (Strong Buy) |
71.00 (64.95) |
-8.52% | Details | |
| 5/9/2019 | Flexion Therapeutics | FLXN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/9/2019 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2019 | Mylan | MYL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2019 | Flexion Therapeutics | FLXN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/25/2019 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/19/2019 | Adamis Pharmaceuticals | ADMP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2019 | Antares Pharma | ATRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/28/2019 | ANI Pharmaceuticals | ANIP | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/27/2019 | Mylan | MYL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2019 | Teva Pharma | TEVA | Upgrade | Outperform (Market Perform) |
19.12 (13.25) |
-30.7% | Details | |
| 1/30/2019 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2019 | Dermira | DERM | Upgrade | Market Perform (Underperform) |
6.80 (3.50) |
-48.53% | Details | |
| 1/14/2019 | PLx Pharma | PLXP | Downgrade | Market Perform (Outperform) |
4.53 (0.09) |
-98.01% | Details | |
| 1/2/2019 | Adamis Pharmaceuticals | ADMP | Maintain | Outperform (Outperform) |
|
Details | ||
| 8/20/2018 | Lannett Co | LCI | Downgrade | Market Perform (Outperform) |
13.50 (0.69) |
-94.89% | Details |
